The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer

• DOI: 10.3892/ijo.2015.2921
• Publication Date: 2015-03-06T13:33:14Z
• Authors: JIN LI; JIE TING ZHANG; XIAOHUA JIANG; XIAOSHUN SHI; JIANFEI SHEN; FENGLAN FENG; JINGYI CHEN; GUIHONG LIU; PING HE; JUHONG JIANG; LAI LING TSANG; YAN WANG; RAFAEL ROSELL; LONG JIANG; JIANXING HE; HSIAO CHANG CHAN
• Keywords: Adult; Male; Mice, Inbred BALB C; Epithelial-Mesenchymal Transition; Lung Neoplasms; Blotting, Western; Cystic Fibrosis Transmembrane Conductance Regulator; Down-Regulation; Mice, Nude; Kaplan-Meier Estimate; Middle Aged; Immunohistochemistry; Disease-Free Survival; 3. Good health; Mice; 03 medical and health sciences; 0302 clinical medicine; Carcinoma, Non-Small-Cell Lung; Biomarkers, Tumor; Animals; Humans; Female; Aged

An increased risk of non-small cell lung cancer (NSCLC) in cystic fibrosis (CF) patients and carriers CF transmembrane conductance regulator (CFTR) mutations has been proposed. However, the role CFTR remains controversial. In present study, expression was assessed 165 NSCLC tumors 22 normal samples with validation an independent series 131 samples. The effect gain loss on malignant behavior examined. manipulation tumor metastasis examined a mouse model. Expression downregulated (p=0.041). Low correlated advanced stage (p<0.001) lymph node (p=0.009). significantly associated poor prognosis (overall survival: 45 vs. 36 months, p<0.0001; progression-free 41 30 p=0.007). Knockdown cells enhanced (epithelial-mesenchymal transition, invasion migration); contrast, overexpression suppressed progression vitro vivo. tumor-suppressing inhibition multiple uPA/uPAR-mediated traits culture. These results show that plays suggest may serve as novel indicator for predicting adverse patients.